Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,850 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo intravenous infusion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

A Low ChloridE hyperTonic Solution for Brain Edema

NCT03204955
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions
Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 28, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT04683848
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
MT-3921, Placebo
Biological
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
XmAb5871, Placebo to match XmAb5871
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
La Jolla, California • Loma Linda, California • San Leandro, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 28, 2026, 9:47 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

NCT03059355
View directory record Official record
Conditions
Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions
UCMSCs, BMMSCs, Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 9:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

NCT04320615
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Tocilizumab (TCZ), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
23
States / cities
La Jolla, California • La Mesa, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Metoclopramide for Post Traumatic Headache

NCT03220958
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Metoclopramide, Diphenhydramine, Normal saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

NCT02043548
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
tocilizumab, placebo
Drug
Lead sponsor
Chester Oddis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Kansas City, Kansas • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

NCT00760565
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
RO4905417, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Gainesville, Florida • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 9:47 PM EDT
Recruiting Phase 2 Interventional

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT07589595
View directory record Official record
Conditions
Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

NCT01662869
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG22515, Placebo, Immune System Activator
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABT-869, paclitaxel, Placebo for ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00108953
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

NCT00297830
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Bone Resorption
Interventions
Zoledronic acid, Alendronate, Placebo Zoledronic Acid, Placebo Alendronate
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 28, 2026, 9:47 PM EDT
Recruiting Phase 3 Interventional

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
52
States / cities
Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 9:47 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 28, 2026, 9:47 PM EDT